About

DepYmed Inc., is a New York based cancer and rare disease therapeutic development company. DepYmed is developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) with its current lead compound, MSI-1436C, in clinical development as a therapeutic candidate for HER2-positive breast cancer. In addition to PTP1B inhibitors, DepYmed has developed a portfolio of small molecules with copper chelating properties which can be applied as potential therapeutic agents for multiple diseases. DepYmed continues to develop the next generation of more potent PTP1B inhibitors / analogs as well as selective copper chelators which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory and continues to explore additional indications that may benefit from using PTP1B inhibitors and selective copper chelators as therapeutic agents.

Management Team

Andreas G. Grill

President & CEO

Board Of Directors

Andreas G. Grill

President & CEO / Director

Sam Backenroth

Director

Peter Young

Director

Thomas M. Riedhammer, Ph.D.

Director

Shankar Hariharan, Ph.D.

Director

Steve Winick

​Director

Scientific Advisory Board

Prof. Nicholas Tonks, Ph.D.

​​Professor at Cold Spring Harbor Laboratory

Investors

csh

Cold Spring Harbor Laboratory

Read More
ohr

Ohr Pharmaceutical

Read More
al

Accelerate Long Island

Read More
top

TOPSPIN FUND, L.P.

Read More
placeholder-image4

Jove Equity Partners, LLC

Read More